dexloxiglumide Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central PubChem

Active Ingredient History

NOW
  • Now
Dexloxiglumide is a drug which acts as a cholecystokinin antagonist, selective for the CCKA subtype. It inhibits gastrointestinal motility and reduces gastric secretions, and despite older selective CCKA antagonists such as lorglumide and devazepide having had only limited success in trials and ultimately never making it into clinical use, dexloxiglumide is being investigated as a potential treatment for a variety of gastrointestinal problems including irritable bowel syndrome, dyspepsia, constipation and pancreatitis, and has had moderate success so far although trials are still ongoing.   Wikipedia

Chemistry

  • SMILES: CCCCCN(CCCOC)C(=O)[C@@H](CCC(=O)O)NC(=O)c1ccc(Cl)c(Cl)c1
  • InChIKey: QNQZBKQEIFTHFZ-GOSISDBHSA-N
  • Mol. Mass: 461.39
  • ALogP: 4.01
  • ChEMBL Molecule:
    dexloxiglumide  
More Chemistry

Pharmacology

Alternative names

cr 2017 | dexloxiglumide | d-loxiglumide

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Dyspepsia (Phase 2)

Irritable Bowel Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue